

LEE S. MARCUS, MD, MS, FACC, FASPC

Curriculum Vitae

307 E 63rd Street
New York, NY 10065

(646) 661-2427
drmarcus@pcny.nyc

PROFESSIONAL EXPERIENCE

President	Preventive Cardiology of NY New York, New York	07/2015-Present
Chief Medical Officer/ Chair- MAB	Arterial Health International Atlanta, Georgia	04/2016-Present
Medical Director/ Chief Science Officer	Optimal Executive/Optimal Wellness Group New York, New York	04/2014-07/2015
Editor in Chief	Empowered Doctor New York, New York	04/2014-07/2015
Director/Analyst	Global Markets Intelligence-Healthcare IPREO, LLC New York, New York	11/2011-03/2014
Medical Director	CareCore Cardiology Bluffton, South Carolina	09/2009-11/2011
Medical Director	REVV Medical Diagnostic, PC Ronkonkoma, New York	08/2009-Present
Cardiologist/ Board Member	The Heart Center Poughkeepsie, New York	07/1999-08/2009

MEDICAL TRAINING

Fellowship	Yale University School of Medicine Yale-New Haven Hospital <i>Nuclear Cardiology</i>	07/1998-06/1999
Fellowship	Yale University School of Medicine Yale-New Haven Hospital <i>Cardiovascular Medicine</i>	07/1996-06/1998

LEE S. MARCUS, MD, MS, FACC, FASPC
C.V., Page Two

Fellowship	Columbia University Columbia-Presbyterian Medical Center <i>Circulatory Physiology/ Congestive Heart Failure/ Cardiac Transplantation</i>	07/1994-06/1996
------------	---	-----------------

Chief Residency/ Residency	New York Medical College Westchester Medical Center <i>Internal Medicine</i>	07/1990-06/1994
-------------------------------	--	-----------------

EDUCATION

Medical	New York Medical College M.D.	06/1990
---------	----------------------------------	---------

Undergraduate	Muhlenberg College B.S. (Cum Laude) <i>Natural Science; Philosophy</i>	06/1986
---------------	--	---------

Graduate	Pace University- Lubin School of Business M.S. as Valedictorian- <i>Finance</i>	05/2014
----------	--	---------

LICENSURE AND CERTIFICATION

M.D.	New York State License	03/04/1992
------	------------------------	------------

Diplomate	American Board of Internal Medicine <i>Cardiovascular Disease</i> - Certification and Recertification	1998, 2008
-----------	---	------------

Certification Board of Nuclear Cardiology- <i>Nuclear Cardiology</i> Certification and Recertification	1999, 2009
--	------------

American Board of Internal Medicine <i>Internal Medicine</i> -expired	1993
--	------

National Board of Medical Examiners	1991
-------------------------------------	------

AFFILIATIONS

Fellow-American College of Cardiology
Fellow-American Society for Preventive Cardiology
American Medical Association
Heart Failure Society of America
National Lipid Association
American Society of Nuclear Cardiology
Trustee- CEO Trust
New York State PBA State Police Surgeon

LEADERSHIP POSITIONS

Credentials Committee- St. Francis Hospital Poughkeepsie, New York	2004-2009
Founder and Medical Director- Congestive Heart Failure Unit/ Congestive Heart Failure Program- Vassar Brothers Medical Center Poughkeepsie, New York	2000-2009
Director- Congestive Heart Failure Program- St. Francis Hospital Poughkeepsie, New York	2000-2009
Director- Nuclear Cardiology/ Radiation Safety Officer The Heart Center - Poughkeepsie, New York	1999-2009
Board President- Dutchess/ Ulster County Chapter- American Heart Association- Poughkeepsie, New York	2006-2008
Board Member- The Heart Center Poughkeepsie, New York	2003-2004

HONORS AND AWARDS

Beta Gamma Sigma Business Honor Society	2014
Listed in Castle Connolly America's Top Doctors	2006-2009
New York State Patient's Choice Award (voted on by patients)	2008, 2009
Listed in Hudson Valley Magazine as One of the <i>Top Physicians in the Hudson Valley</i>	2006-2009
Key Volunteer Service Award - Dutchess-Ulster Division American Heart Association	2006-2007
Most Outstanding Resident Teaching Award New York Medical College	1991, 1992, 1993

LEE S. MARCUS, MD, MS, FACC, FASPC
C.V., Page Four

CURRENT CONSULTING POSITIONS

Scientific Advisory Board Xablecath, Inc.	07/2015- Present
Medical Advisory Board Cognate Nutritionals	06/2015- Present
Medical Director NFL Alumni Association Wellness Challenge	07/2014- Present

CONSULTANT AND LECTURER

Gerson Lehrman Group
St. Jude Medical
Glaxo-Smithkline
Astra-Zeneca
Scios- Johnson & Johnson
AtCor Medical

BIBLIOGRAPHY/ORIGINAL PAPERS

Marcus, LS; Hart, D; Packer, M; Katz, SD, et al: Hemodynamic and Renal Excretory effects of Human Brain Natriuretic Peptide Infusion in Patients with Congestive Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Cross-Over Trial
Circulation: 1996, 94: 3184-3189

Sun, BC; Catanese, KA; Spanier, TB; Flannery, MR; Gardocki, MT; **Marcus, LS**; Levin, HR; Rose, EA; Oz, MC: 100 Long-Term Implantable Left Ventricular Assist Devices: The Columbia-Presbyterian Experience
Annals of Thoracic Surgery, 1999;68:688-694

ABSTRACTS

Marcus, LS; Pollack, BD; Corbisiero, R.; Blake, JW; Do Recovery ST-segment Changes Following Exercise Treadmill Testing Enhance Sensitivity and Predictive Value?
Clinical Research; Oct. 1993;41:609

Marcus, LS; Yushak, M.; Medina, N; Katz, SD: Assessment of Pulmonary Vascular Reactivity with Human Brain Natriuretic Peptide: Comparison with Nitroprusside
Journal of Heart and Lung Transplantation. 1996; 15:1pt2 S84

Goldstein, D; Choudri, A; Garfein, ES; Flannery, M.; **Marcus, LS**; Rose, EA; Oz, MC: Experience with Long Term LVAD Support: Implications for Permanent Use
Journal of Heart and Lung Transplantation 1998; 17 (1):63

Russell, RR; **Marcus, LS**; Rife, F; Tamborlane, WV; Wackers, FJTh; Young, LH; Diminished Cardiac Response to Insulin Induced Hypoglycemia in Patients with Type I Diabetes: **Diabetes**

LEE S. MARCUS, MD, MS, FACC, FASPC
C.V., Page Five

ADDITIONAL CLINICAL RESEARCH (Partial List)

Effects of Insulin Induced Hypoglycemia on Left Ventricular Function and Autonomic Balance in Diabetic and Non-Diabetic Patients. (Yale University) **1998-1999**

Randomized Evaluation of Mechanical Assist Therapy in Congestive Heart Failure (**REMATCH Trial**) (Columbia University College of Physicians and Surgeons) **1994-1996**

Phase II Randomized Multicenter Trial of Twice Daily Deltaparin (Fragmin) versus Intravenous Heparin with Accelerated Infusion of rt-Alteplase (Activase) in Acute Myocardial Infarction (**ASSENT PLUS Study**) **Sub-investigator; 1999-2000**

Phase III, Randomized, Open Label Trial Evaluating the Efficacy and Safety of Reopro (Abciximab) in Combination with Reduced Dose Reteplase for Treatment of Acute Myocardial Infarction (**GUSTO IV MI Study**) **Sub-investigator; 1999-2000**

Multicenter, Double Blind Study Comparing the Efficacy and Safety of Long Term Treatment with Valsartan, Captopril and Their Combination in High Risk Patients after Myocardial Infarction (**VALIANT Study**) **Sub-investigator; 1999-2003**

Candesartan Cilexetil in Heart failure: Assessment of Reduction in Mortality and Morbidity (**CHARM Study**). **Principal Investigator; 1999-2003**

Viagra in Congestive Heart Failure and CAD: A double blind, randomized, placebo controlled, parallel group, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra, in males with erectile dysfunction. **Principal Investigator; 2001-2002**

SYNERGY: A Prospective, Randomized, Open Label, Multicenter Study In Patients Presenting With Acute Coronary Syndromes (ACS) Protocol ENO.GMA.301. **Sub-Investigator; 2002-2004**

ADVANCE MI: Protocol No. 01-042: Addressing the Value of Primary Angioplasty After Combination Therapy or Eptifibatide Monotherapy In Acute Myocardial Infarction. **Sub-Investigator; 2002-2003**

IMPACT STUDY: The IMPACT of Medical Subspecialty on Patient Compliance to Treatment with ADVICOR. **Principle Investigator; 2002**

STAMINA-HFP: Registry study of Anemia in a Heart Failure Population. **Principle Investigator; 2003**

ACUITY: A randomized comparison of Angiomax (bivalirudin) versus lovenox/Clexane (enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST- segment elevation. **Sub-Investigator; 2003-2006**

EARLY-ACS: Early Glycoprotein IIa/IIIb inhibition in Non-ST segment Elevation Acute Coronary Syndrome: A randomized Trial Evaluating the Clinical Benefits of Early Front-Loaded Eptifibatide in the Treatment of Patients with Non-ST segment Elevation Acute Coronary Syndrome. **Sub-Investigator; 2004-2009**

LEE S. MARCUS, MD, MS, FACC, FASPC
C.V., Page Six

JUPITER: Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin: A Randomized, Double Blind, Multicenter, Phase III Study of Rosuvastatin (Crestor) 20 mg in the Primary Prevention of cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein. Sub- Investigator; 2005-2008

FUSION II: Follow-up Serial Infusions of Natreacor (nesiritide) for the Management of Patients with Heart Failure. **Principle Investigator; 2004-2007**

TRIAL TO ASSESS CHELATION THERAPY (TACT): grant # 1 UO1 ATOO1156-01 Study
Sponsors: National Institutes of Health (NCCAM and NHLBI) **Sub- Investigator; 2004-2008**

USE-BNP STUDY: Utilizing, Studying, Evaluating BNP for monitoring in subjects with heart failure.
Sponsor: Siemens Medical Solutions Diagnostics. **Principle Investigator; 2007-2009**

ASCEND-HF TRIAL: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure. **Principle Investigator; 2007-2009**